Company Overview and News
There seems to be no letup in the powerful momentum with Netflix, Inc. (NASDAQ:NFLX). During the latest earnings report, revenues jumped by 43% and the company added 7.4 million new subscribers. The current membership base is now at 125 million.
San Francisco: Former Yahoo chief executive officer (CEO) Marissa Mayer is starting a technology business incubator, Lumi Labs, with longtime colleague Enrique Munoz Torres.
Caught between obligations to shareholders and employees, IBM (NYSE:IBM) was unable to commit to the $1 billion per quarter needed to compete in cloud early in this decade. It is now paying the price.
Over the last five trading days, telecom stocks were initially slow off the blocks but gradually picked up pace, as protective measures by the U.S. government seemed to propel the industry to gain an upper hand over its Chinese counterparts. At a meeting held last week, the Federal Communications Commission (“FCC”) came up with a concrete date to auction licenses of high-band spectrum so that wireless networks could roll out 5G technology by the end of the year.
Verizon Communications Inc. (VZ - Free Report) is scheduled to release first-quarter 2018 results before the opening bell on Apr 24. The company is likely to record higher revenues from the Wireless segment, which accounts for the lion’s share of total revenues, on a year-over-year basis. Whether this will benefit the bottom line of the company remains to be seen. Top-Line Expansion Verizon offers one of the most efficient wireless networks in the United States.
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Today Verizon Communications Inc. (NYSE:VZ) (Nasdaq:VZ) closed its acquisition of Moment, a New York-based design and strategy firm founded in 2002. Beginning immediately, employees will join the company’s growing in-house design team and be responsible for creating end-to-end customer experiences including in-store, online, mobile and live customer service by phone or chat.
Twenty-First Century Fox Inc , which has agreed to sell most of its assets to Walt Disney Co , rejected a deal with another entity that a source identified as Comcast Corp due to higher regulatory risks.
I’ve long believed that one of the worst strategies in the market is for investors to “rotate” into so-called defensive stocks. It’s a common piece of advice from experts, particularly in a more volatile market. The strategy sounds cautious, and even wise. In a nervous market, investors should migrate to lower-risk stocks in order to protect their capital.
Apple Inc. (NASDAQ: AAPL) began taking orders for its new iPhone 8 on September 15 last year and began shipping to customers one week later. The new device was not an instant hit because everyone was waiting for the iPhone X, the top of the line phone that was due for release on November 3.
T-Mobile US, Inc. (TMUS - Free Report) has agreed to pay a fine of $40 million to the U.S. Treasury to resolve a dispute with the government. The company was accused of failing to fix problems relating to phone calls in rural areas and using false ring tones, which were banned, to give the impression that the faulty calls were actually getting through. T-Mobile accepted the charges and acknowledged that false ring tones were used on hundreds of millions of long-distance rural calls in violation of Federal Communications Commission (“FCC”) rules.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET